sinus pressure; nose was completely clogged; not able to breathe; may have attacked the nerves in her face; covid-19; migraine; flu and the infection and flu attacking the patient's facial nerves.; covid-19 infection; turned into a flu; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. Other Case identifier(s): 2022BHV00019.  A 36 year-old female patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose 2, single and (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation. Relevant medical history included: "Autoimmune thyroiditis" (ongoing). The patient's concomitant medications were not reported. Past drug history included: Nurtec odt for Migraine, reaction(s): "It did not really kick in until 3:25 PM", notes: Daily dose: (75 mg, 1 tablet once a day), Rout of administration: oral, Therapy dates 21Jan2022-unk; Nurtec odt for Migraine, reaction(s): "Off label use: Facial migraine", notes: Daily dose: (75 mg, 1 tablet once a day), Rout of administration: oral, Therapy dates 21Jan2022-unk. The following information was reported: DRUG INEFFECTIVE (medically significant), outcome "unknown", described as "covid-19"; SUSPECTED COVID-19 (medically significant) with onset 03Jan2022, outcome "recovered" (17Jan2022), described as "covid-19 infection"; PARANASAL SINUS DISCOMFORT (non-serious), outcome "unknown", described as "sinus pressure"; NASAL CONGESTION (non-serious), outcome "unknown", described as "nose was completely clogged"; DYSPNOEA (non-serious), outcome "unknown", described as "not able to breathe"; NERVE INJURY (non-serious), outcome "unknown", described as "may have attacked the nerves in her face"; INFLUENZA (non-serious) with onset Jan2022, outcome "unknown", described as "turned into a flu"; MIGRAINE (non-serious), outcome "unknown", described as "migraine"; FACIAL NERVE DISORDER (non-serious), outcome "unknown", described as "flu and the infection and flu attacking the patient's facial nerves.". Therapeutic measures were not taken as a result of suspected covid-19. Therapeutic measures were taken as a result of paranasal sinus discomfort, nasal congestion, migraine. It was reported that patient took her first dose of Nurtec ODT (rimegepant) on 12Jan2022 at 12:00 and it did not kick in until 15:25. Patient was put on Nurtec ODT (rimegepant) due to clogged nose for two and half weeks. Her doctor said that it was a form of migraine. Patient confirmed that she did not have a headache, it was just sinus pressure, her nose was completely clogged, and she was not able to breathe. Patient stated that she had COVID-19 infection from 03Jan2022 to 17Jan2022, which turned into a flu. The doctor noted that the COVID-19 infection and flu may have attached the nerves in her face. Treatment included Excedrin. (Caffeine/paracetamol) for migraine. At the time of the report, Nurtec ODT (rimegepant) was discontinued, and the outcome of the events therapeutic product effect delayed (It did not really kick in until 15:25) and off label use (Off label use: Facial migraine) was unknown. Patient stated that she did not take Nurtec ODT (rimegepant) after the event and will not take it anymore. The events were still ongoing and patient was still waiting for a diagnosis. Patient was double vaccinated and was not due for her booster at the time of report. NasoGel (Aloe vera, Hyaluronate sodium, sodium chloride) was used for Paranasal sinus discomfort and nasal congestion (21Jan2022-unknown).  The lot number for bnt162b2 was not provided and will be requested during follow up.